ambroxol has been researched along with Pulmonary Disease, Chronic Obstructive in 20 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess in a randomized clinical trial the influence of perioperative short-term ambroxol administration on postoperative complications, hospital stay and costs after pulmonary lobectomy for lung cancer." | 5.14 | Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial. ( Brunelli, A; Di Nunzio, L; Refai, M; Sabbatini, A; Salati, M; Sciarra, V; Socci, L; Xiumé, F, 2009) |
| "Ambroxol is frequently used as mucolytic agent in respiratory diseases associated with increased mucus production like acute or chronic bronchitis." | 4.84 | Antiinflammatory properties of ambroxol. ( Beeh, KM; Beier, J; Esperester, A; Paul, LD, 2008) |
| "Patients with stable chronic obstructive pulmonary disease (COPD) have been observed to benefit from tiotropium bromide." | 3.01 | Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease. ( Fang, Q; Gao, X; Yan, Z; Yu, S; Zhang, C, 2021) |
| "Patients in the COPD treatment group received what was termed "lung-protective treatment" including ambroxol, budesonide and ipratropium bromide in addition to chest physiotherapy." | 2.84 | Correlation Between Tumor Necrosis Factor-α and Interleukin-1β in Exhaled Breath Condensate and Pulmonary Function. ( Chi, M; Fan, Y; Li, X; Lin, X; Sun, D; Wang, X; Zhang, X, 2017) |
| "In the patients with COPD concurrent with CHD, the combined drug ascoril exerts broncholytic and expectorant effects, with no pronounced negative action on HR." | 2.78 | [The combined drug ascoril in the treatment of patients with chronic obstructive pulmonary disease concurrent with coronary heart disease]. ( Grigor'eva, NIu; Koroleva, ME; Koroleva, TV; Kuznetsov, AN, 2013) |
| "The use of Ambroxol in COPD exacerbations corrected AOF production in the blood of the patients and enhanced the efficiency of their treatment." | 2.75 | [Effect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease]. ( Farkhutdinov, RR; Farkhutdinov, ShU; Farkhutdinov, UR; Mirkhaĭdarov, AM; Petriakov, VV, 2010) |
| "Ninety AECOPD patients were randomly divided into Tanreqing group, ambroxol hydrochloride group and control group." | 2.73 | [A study of the mechanism of Qingre Huatan therapy in treatment of acute exacerbation of chronic obstructive pulmonary disease by improving airway inflammation and mucus hypersecretion]. ( Chang, J; Guo, J; Li, W; Mao, B; Wan, MH; Wang, G; Wang, L; Zhang, Y, 2008) |
| "Sixty patients with mild stable COPD were recruited." | 2.70 | Neltenexine tablets in smoking and non-smoking patients with COPD. A double-blind, randomised, controlled study versus placebo. ( Cattaneo, C, 2001) |
| "Ambroxol also has a protective effect on the lungs during extracorporeal bypass, ameliorating inflammatory reaction and oxygen stress and preserving pulmonary surfactant." | 2.50 | Does ambroxol confer a protective effect on the lungs in patients undergoing cardiac surgery or having lung resection? ( Chen, X; Huang, D; Ma, Q; Wang, S, 2014) |
| "Chronic obstructive pulmonary disease (COPD) is an important risk factor for perioperative morbidity and mortality in patients undergoing cardiac surgery." | 1.37 | Fast-track pulmonary conditioning before urgent cardiac surgery in patients with insufficiently treated chronic obstructive pulmonary disease. ( Dreger, H; Gromann, T; Hetzer, R; Melzer, C; Schaumann, B, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, S | 1 |
| Zhang, C | 1 |
| Yan, Z | 1 |
| Fang, Q | 1 |
| Gao, X | 2 |
| Potyazhenko, MM | 1 |
| Ishcheikin, KY | 1 |
| Nastroga, TV | 1 |
| Sokolyuk, NL | 1 |
| Kitura, OY | 1 |
| Gorodnytska, IM | 1 |
| Wang, J | 1 |
| Cui, Z | 1 |
| Liu, S | 1 |
| Gao, P | 1 |
| Shi, Y | 1 |
| Guo, S | 1 |
| Li, P | 1 |
| Cazzola, M | 1 |
| Rogliani, P | 1 |
| Calzetta, L | 1 |
| Hanania, NA | 1 |
| Matera, MG | 1 |
| Lin, X | 1 |
| Fan, Y | 1 |
| Wang, X | 1 |
| Chi, M | 1 |
| Li, X | 1 |
| Zhang, X | 1 |
| Sun, D | 1 |
| Grigor'eva, NIu | 1 |
| Kuznetsov, AN | 1 |
| Koroleva, TV | 1 |
| Koroleva, ME | 1 |
| Dhar, R | 1 |
| Wang, S | 1 |
| Huang, D | 1 |
| Ma, Q | 1 |
| Chen, X | 1 |
| Ge, LT | 1 |
| Liu, YN | 1 |
| Lin, XX | 1 |
| Shen, HJ | 1 |
| Jia, YL | 1 |
| Dong, XW | 1 |
| Sun, Y | 1 |
| Xie, QM | 1 |
| Li, W | 1 |
| Mao, B | 1 |
| Wang, G | 1 |
| Wang, L | 1 |
| Chang, J | 1 |
| Zhang, Y | 1 |
| Wan, MH | 1 |
| Guo, J | 1 |
| Beeh, KM | 1 |
| Beier, J | 1 |
| Esperester, A | 1 |
| Paul, LD | 1 |
| Refai, M | 1 |
| Brunelli, A | 1 |
| Xiumé, F | 1 |
| Salati, M | 1 |
| Sciarra, V | 1 |
| Socci, L | 1 |
| Di Nunzio, L | 1 |
| Sabbatini, A | 1 |
| Farkhutdinov, UR | 1 |
| Farkhutdinov, RR | 1 |
| Petriakov, VV | 1 |
| Farkhutdinov, ShU | 1 |
| Mirkhaĭdarov, AM | 1 |
| Dreger, H | 1 |
| Schaumann, B | 1 |
| Gromann, T | 1 |
| Hetzer, R | 1 |
| Melzer, C | 1 |
| Malerba, M | 1 |
| Ponticiello, A | 1 |
| Radaeli, A | 1 |
| Bensi, G | 1 |
| Grassi, V | 1 |
| Akkoca Yildiz, O | 1 |
| Fadda, G | 1 |
| Cattaneo, C | 1 |
| Jahnz-Rózyk, K | 1 |
| Kucharczyk, A | 1 |
| Chciałowski, A | 1 |
| Płusa, T | 1 |
| Nowak, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for ambroxol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Topics: Acetylcysteine; Ambroxol; Carbocysteine; Disease Progression; Expectorants; Humans; Network Meta-Ana | 2017 |
Role of mucolytics in wet cough.
Topics: Ambroxol; Asthma; Bronchodilator Agents; Cholinergic Antagonists; Cough; Cystic Fibrosis; Expectoran | 2013 |
Does ambroxol confer a protective effect on the lungs in patients undergoing cardiac surgery or having lung resection?
Topics: Aged; Ambroxol; Benchmarking; Cardiac Surgical Procedures; Evidence-Based Medicine; Expectorants; Fe | 2014 |
Antiinflammatory properties of ambroxol.
Topics: Administration, Oral; Ambroxol; Anti-Inflammatory Agents; Bronchitis; Humans; Inflammation; Pharyngi | 2008 |
[Ambroxol].
Topics: Ambroxol; Anti-Inflammatory Agents; Antioxidants; Asthma; Bronchial Hyperreactivity; Cystic Fibrosis | 2006 |
[Antioxidative features of ambroxol--usefulness in COPD].
Topics: Ambroxol; Antioxidants; Expectorants; Humans; Pulmonary Disease, Chronic Obstructive | 2001 |
10 trials available for ambroxol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Ambroxol; Calcium; Computational Biology; Double-Blind Method; Formotero | 2021 |
Correlation Between Tumor Necrosis Factor-α and Interleukin-1β in Exhaled Breath Condensate and Pulmonary Function.
Topics: Aged; Ambroxol; Breath Tests; Budesonide; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interle | 2017 |
[The combined drug ascoril in the treatment of patients with chronic obstructive pulmonary disease concurrent with coronary heart disease].
Topics: Adult; Aged; Ambroxol; Antitussive Agents; Comorbidity; Coronary Disease; Dextromethorphan; Expector | 2013 |
[A study of the mechanism of Qingre Huatan therapy in treatment of acute exacerbation of chronic obstructive pulmonary disease by improving airway inflammation and mucus hypersecretion].
Topics: Aged; Ambroxol; Anti-Inflammatory Agents; Diagnosis, Differential; Drug Therapy, Combination; Drugs, | 2008 |
Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial.
Topics: Aged; Ambroxol; Cost-Benefit Analysis; Female; Humans; Length of Stay; Lung Neoplasms; Male; Periope | 2009 |
[Effect of mucolytic therapy on the production of reactive oxygen species in the blood of patients with an exacerbation of chronic obstructive pulmonary disease].
Topics: Ambroxol; Disease Progression; Drug Therapy, Combination; Expectorants; Female; Humans; Male; Middle | 2010 |
Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).
Topics: Administration, Oral; Adult; Aged; Ambroxol; Double-Blind Method; Expectorants; Female; Humans; Male | 2004 |
Oral neltenexine in patients with obstructive airways diseases: an open, randomised, controlled comparison versus sobrerol.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambroxol; Expectorants; Female; Humans; Male; | 2001 |
Neltenexine tablets in smoking and non-smoking patients with COPD. A double-blind, randomised, controlled study versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Double-Blind Method; Female; Humans; Male; Middle Aged; Pu | 2001 |
[The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients].
Topics: Administration, Inhalation; Aged; Ambroxol; Double-Blind Method; Expectorants; Female; Humans; Male; | 2001 |
4 other studies available for ambroxol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Optimization of pathogenetic therapy in patients with chronic obstructive lung disease.
Topics: Ambroxol; Expectorants; Humans; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2020 |
Early use of noninvasive techniques for clearing respiratory secretions during noninvasive positive-pressure ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease and hypercapnic encephalopathy: A prospective cohort stud
Topics: Aged; Albuterol; Ambroxol; Brain Diseases; Equipment Design; Feasibility Studies; Female; Humans; Hy | 2017 |
Inhalation of ambroxol inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway.
Topics: Acute Lung Injury; Administration, Inhalation; Ambroxol; Animals; Cells, Cultured; Cytokines; Diseas | 2016 |
Fast-track pulmonary conditioning before urgent cardiac surgery in patients with insufficiently treated chronic obstructive pulmonary disease.
Topics: Aged; Airway Resistance; Albuterol; Ambroxol; Bronchodilator Agents; Budesonide; Cardiac Surgical Pr | 2011 |